Revolutionary 3 Shares - Part 2- CRISPR Therapeutics

  Revolutionary 3 Shares - Part 2- CRISPR Therapeutics 2-CRISPR Therapeutics CRISPR Therapeutics; It is a biotechnology that focuses on developing treatments for serious diseases such as cancer and blood diseases without side effects. The company mainly conducts studies on immunotherapy and gene therapy. Around 360,000 babies worldwide are born each year with either sickle cell disease (SCD) or beta thalassemia. In the former case, the patient's hemoglobin is distorted. This can lead to a life-threatening condition called a Vaso-occlusive crisis (VOC). Beta thalassemia can significantly reduce the patient's hemoglobin level. In either case, patients require hospitalization for frequent blood transfusions. Apart from bone marrow transplantation, there is no cure for these two diseases. Revolutionary 3 Shares - Part 2- CRISPR Therapeutics However, CRISPR Therapeutics can change this situation. In phase 1/2 clinical trials, patients receiving CTX001 gene therapy transfusions had normalized hemoglobin levels, were VOC-free, and were no longer transfusion dependent. In addition, thanks to the company's CTX110 immunotherapy, positive advances have been made in patients with lymphoma. Currently, CRISPR Therapeutics, whose immunotherapies are successfully making their way to the market, are at an advantage in the face of the appreciation of companies that produce drugs to treat SCD. CRISPR Therapeutics owns more than $ 1.69 billion in cash, despite a loss of $ 348,9 million a year. Given the financial and scientific strength of the company, it is positioned as one of the stocks that should be held in the long run.      

Source: The Montley Fool

 

You may also be interrested in

 

Musk will build the city of Starbase to make satellites